Clinical Trial Update: Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for safety and tolerability of Arikayce in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection (Phase 1/2; completed; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Arikayce (amikacin liposome inhalation suspension)

Snippet

Sponsor: Insmed Incorporated | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-06-04